Objective The course of disease in juvenile idiopathic arthritis ( JIA) is unpredictable with episodes of activity and remission. In order to identify predictive factors, 93 SNPs, JIA subtype, age at onset and ANA status were studied in relation to disease course. Methods Genetic and clinical parameters were analysed in a cohort of 272 Caucasian patients with persistent oligoarthritis (n=129), extended oligoarthritis (n=57) and rheumatoid factor negative polyarthritis (n=86). Categories of disease course (remitting (n=65), intermediate (n=96) and unremitting (n=111)) were designed based on the cumulative time spent in active disease in the first 2 years. Results Univariate analysis revealed association of the course of disease with JIA subtype ( p=5.7*10 ), VTCN1 rs12 046 117 ( p=0.017) and CDK6 rs42 041 ( p=0.038). In a subsequent multivariate ordinal logistic regression analysis, VTCN1 rs10 923 223 (OR 0.41, 95%-CI 0.26 to 0.63) and JIA subtype (OR 3.8, 95%-CI 2.0 to 7.2; OR 2.5, 95%-CI 1.4 to 4.2, for extended oligoarthritis and RF-negative polyarthritis vs persistent oligoarthritis, respectively) were the strongest independent factors for course of disease. Conclusions This study provides evidence that VTCN1, encoding B7-H4, is associated with course of disease in selected subtypes of JIA. VTCN1 might be useful in predicting the course of disease.
INTRODUCTION
Juvenile idiopathic arthritis ( JIA) is a heterogeneous group of disorders characterised by chronic inflammation of the joint(s). JIA is thought to be an autoimmune disease in which the immune response is deregulated. 1 Clinical course and outcome are of great importance to patients, parents and physician. In outcome studies using a variety of criteria for remission, an overall remission rate of 40% has been reported. The highest remission rate was consistently observed in persistent oligoarthritis compared to extended oligoarthritis and rheumatoid factor (RF)-negative polyarthritis. [2] [3] [4] Because the course of disease is unpredictable and fluctuating in all JIA subtypes with episodes of active and inactive disease, the cumulative time spent in a state of active disease is an accurate measure for the disease activity over time. [4] [5] [6] Since it is unethical to study patients who do not receive treatment, course of disease is inevitably defined for patients receiving treatment if and when necessary. The percentage of active disease in the first years is not only predictive for the course of disease in the following years, 2 6 but a prolonged disease activity is also related to damage to the joints or functional impairment. 7 The aim of treatment is to minimise the time spent in active disease.
No clinical parameters or biomarkers are available at disease onset to predict the course of disease. 8 Genetic markers would be ideal as predictive factors, already present at disease onset and not influenced by disease activity or medication. Recently, a number of genetic susceptibility factors for JIA (eg, HLA, PTPN22, PTPN2 and IL2RA) have been described and replicated by means of genome-wide and candidate gene association studies.
9-11 Some of these genetic risk factors are also involved in other autoimmune diseases.
The aim of this study was to identify genetic factors associated with severity of JIA. The relationship between single nucleotide polymorphisms (SNPs) in candidate genes involved in immunoregulation and autoimmunity, and the percentage of active disease in the first 2 years after diagnosis, was investigated.
MATERIALS AND METHODS Patient population
Two hundred and seventy-two Caucasian JIA patients with persistent oligoarticular, extended oligoarticular and RF-negative polyarticular JIA, of whom DNA and clinical data were available, were studied. Patients, recruited from eight centres throughout northwestern Europe, were diagnosed between 1991 and 2006 and had a follow-up of at least 2 years. Informed consent was obtained from all patients and/or parents, and the review boards of the participating centres approved this study (table 1) .
Clinical data
All hospital visits during the first 2 years after diagnosis have been retrospectively evaluated to determine the state of disease activity at each visit. Inactive disease was defined as the absence of clinically active arthritis, the lowest possible physician's global assessment and an ESR <20 mm/h (following a modified definition of clinically inactive disease). 12 The cumulative time spent in active disease in the first 2 years was determined, and formed the basis for the categories of disease course 6 : remitting (<= 35% active disease), intermediate (35-65% active disease) and unremitting (>= 65% active disease) (table 1).
Genetic factors
SNPs numbering 112 in 65 genetic regions were genotyped, because of their association with JIA, other autoimmune diseases, and/or their role in immunoregulation (see online supplementary table S1).
Statistical analysis
The three categories representing course of disease were used as outcome parameter. Univariate analysis was performed with the clinical parameters JIA subtype, age at onset and ANA status using χ 2 and Kruskal-Wallis tests, and with the genetic parameters comparing the genotype distribution of each SNP between the categories of disease course with a linear by linear trend test. The linkage disequilibrium of associated SNPs (p<0.05) was studied using parental data (Haploview). 13 Parameters with a p value<0.05 in the univariate analysis were analysed by multivariate ordinal logistic regression. ORs and 95% CIs are presented. A p value<0.001 was considered significant after Bonferroni correction for multiple testing (57 successfully typed genes/loci). ROC curves were plotted for two models with different parameters predicting course at disease onset (see online supplementary table S2 and figure S1). A casecontrol analysis was performed with the SNPs that were associated with course of disease ( p<0.05), to evaluate their role in susceptibility to JIA (see online supplementary table S3). Data were analysed using IBM SPSS Statistics V.20.
RESULTS
Ninety-three out of 112 SNPs (83%) located in 57 genes/loci were successfully genotyped in 272 patients (see online supplementary table S1). This cohort consisted of 65 patients with a remitting course of disease, 96 patients with an intermediate course, and 111 patients with an unremitting course (table 1) .
In univariate analysis, JIA subtype, but not ANA status or age at onset, was significantly associated with the course of disease; the persistent oligoarthritis patients had more intermediate and remitting disease course, whereas the majority of extended oligoarthritis and RF-negative polyarthritis patients followed an unremitting disease course ( p=5.7*10 −5 ) (table 2) . Comparing the genotype distribution in the three categories reflecting course of disease revealed three SNPs that were associated (p<0.05). Two of these SNPs were located in the VTCN1 gene, rs10 923 223 ( p=4.4*10 −5 ) and rs12 046 117 ( p=0.017), and a third association was found with CDK6 rs42 041 (p=0.038) (table 2). The minor alleles of the three SNPs were associated with a remitting course. None of the other investigated SNPs were associated, except a trend towards association with LCK rs695 161 ( p=0.051). Because two of the associated SNPs (rs10 923 223 and rs12 046 117) were located in the VTCN1 gene, the linkage disequilibrium was studied. The two SNPs were highly correlated (D'=0.97; r 2 =0.77). Therefore, we have included only VTCN1 rs10 923 223 in further analyses.
In multivariate ordinal regression analysis, JIA subtype (extended oligoarthritis and RF-negative polyarthritis, with persistent oligoarthritis as reference; extended oligoarthritis OR 3.8, 95%-CI 2.0 to 7.2, p=6. (table 3 ). The addition of VTCN1 rs10 923 223 and CDK6 rs42 041 to a model predicting course of disease at diagnosis in which only subtype at onset is included, increases the AUC of an ROC curve from 0.57 to 0.67 (see online supplementary table S2 and figure S1 ).
DISCUSSION
In this study, we describe that genetic variations in VTCN1 (rs10 923 223 and rs12 046 117) and in CDK6 (rs42 041) are associated with the course of disease in JIA. Our data show a protective effect of the minor allele of all three SNPs on the course of disease. This effect is independent of the association that exists between the JIA subtype and the course of disease. Because CDK6 is involved in cell-cycling, the association of disease course with CDK6 rs42 041 is not unlikely. However, this association is not significant after correction for multiple testing.
Interestingly, the association of VTCN1 with the course of disease is in line with the described function of the encoded protein. VTCN1, V-set domain containing T-cell activation inhibitor 1, encodes B7-H4, a member of the B7 cosignalling molecule family expressed on antigen presenting cells. 14 15 Ligation of B7-H4 has an inhibitory effect on T-cell proliferation and production of cytokines. 14 15 Because of its inhibiting effects on immune responses, B7-H4 has been associated with prognosis in cancer and autoimmunity. 16 17 In B7-H4 deficient mice, an exacerbation of collagen-induced arthritis was observed. 18 An agonistic soluble B7-H4Ig suppressed the progression of collagen-induced arthritis and improved the progression of experimental autoimmune encephalomyelitis. 18 19 Targeting of this inhibitory B7-H4 pathway might be of therapeutic interest, similar to the CTLA4 fusion protein (Abatacept) in rheumatoid arthritis.
In our cohort, no significant association of VTCN1 with the susceptibility to JIA was observed (see online supplementary table S3), but instead an association of the minor allele of rs10 923 223 with a less severe course of disease (table 2) . It is conceivable that the minor allele is associated with a gain of function of VTCN1, leading to a stronger inhibitory signal to activated T cells. This hypothesis implies that VTCN1 does not contribute to initiation but, rather, to the course of the disease. At present, it is very difficult to predict the course of disease at the moment of diagnosis. The addition of VTCN1 and CDK6 to the predictive model for disease course increased the AUC (see online supplementary table S2 and figure S1 ). Although the total predictive power is still limited, it suggests that genetic information may contribute to prognosis in the case of JIA.
It is remarkable that the well-established JIA loci PTPN22, 4q27 (IL2-IL21), 5q11 (ANKRD55) and TNFA were not associated with course of disease, although they were associated with susceptibility in our cohort as well (Reinards et al manuscript in preparation). 9-11 20 This suggests that genes involved in the development of disease are not necessarily involved in the progression of disease. Replication of our data remains necessary since patient numbers are relatively small when comparing categories of disease course. However, if association of VTCN1 with course of disease will be confirmed, these data support the development of therapeutic tools based on interfering with this receptor ligand interaction in JIA, and maybe other autoimmune diseases. 
